{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:31:25Z","timestamp":1783704685392,"version":"3.55.0"},"reference-count":43,"publisher":"Becaris Publishing Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Anticholinergic burden (ACB) is associated with profound clinical and economic burden; however, anticholinergic medications are often prescribed for overactive bladder (OAB). This analysis assessed risk of adverse health outcomes and costs associated with ACB among patients with OAB.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    Adults with \u22651 pharmacy claim for \u22651 OAB anticholinergic medication and continuous coverage for \u22656\u00a0months before and after the first prescription fill date for OAB anticholinergic medication (index) from January 2010 to November 2021 in the Optum Research Database were included. Daily ACB scores were calculated postindex. The impact of ACB on risk of certain adverse health outcomes was examined using Cox proportional hazards regression with categorical and piecewise linear specifications for ACB. Time-varying total ACB association with healthcare costs was evaluated with marginal structural models.\n                    <jats:bold>Results:<\/jats:bold>\n                    Overall, 428,142 patients were included in the analysis; mean (SD) age was 65.2 (14.9) years. Mean (SD) preindex ACB was 0.53 (1.44) points\/day. Postindex, OAB medications accounted for 61.0% (95% CI: 60.9%\u201361.1%) of total ACB. Adjusted hazard ratios for urinary tract infection (UTI), urinary retention, delirium\/drowsiness, cognitive impairment, falls\/fractures and cardiovascular events were &gt;1 (vs 0 points\/day) and increased with ACB. A 1-point\/day increase in ACB was associated with increased risk of UTI, urinary retention, delirium\/drowsiness, cognitive impairment, falls\/fractures and cardiovascular events for patients with ACB \u22648 points\/day preindex. Increasing ACB was associated with increased all-cause total healthcare costs and costs related to cognitive impairment and falls\/fractures.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The association between increased ACB and greater risk of certain adverse health outcomes and costs supports the reassessment of anticholinergic medication use for patients with OAB.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0054","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T11:22:39Z","timestamp":1764760959000},"source":"Crossref","is-referenced-by-count":1,"title":["Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7741-5771","authenticated-orcid":false,"given":"Holly E","family":"Richter","sequence":"first","affiliation":[{"name":"Department of Obstetrics &amp; Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-6001","authenticated-orcid":false,"given":"Benjamin","family":"Chastek","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, MN 55344, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6588-7468","authenticated-orcid":false,"given":"Adam","family":"Carrera","sequence":"additional","affiliation":[{"name":"Sumitomo Pharma America, Inc., Marlborough, MA 01752, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1246-1635","authenticated-orcid":false,"given":"Christina","family":"Steiger","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, MN 55344, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Snyder","sequence":"additional","affiliation":[{"name":"Sumitomo Pharma America, Inc., Marlborough, MA 01752, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7568-2787","authenticated-orcid":false,"given":"Laleh","family":"Abedinzadeh","sequence":"additional","affiliation":[{"name":"Sumitomo Pharma America, Inc., Marlborough, MA 01752, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4998-582X","authenticated-orcid":false,"given":"Tim","family":"Bancroft","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, MN 55344, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-5615","authenticated-orcid":false,"given":"Jeffrey","family":"Nesheim","sequence":"additional","affiliation":[{"name":"Sumitomo Pharma America, Inc., Marlborough, MA 01752, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9838-9178","authenticated-orcid":false,"given":"Roger R","family":"Dmochowski","sequence":"additional","affiliation":[{"name":"Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0911-682X","authenticated-orcid":false,"given":"Adonis K","family":"Hijaz","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Cleveland, OH 44145, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0142-9015","authenticated-orcid":false,"given":"Jeffrey","family":"Frankel","sequence":"additional","affiliation":[{"name":"Seattle Urology Research Center, Seattle, WA 98040, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"12","key":"e_1_3_10_3_2","first-page":"CD003193","article-title":"Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults","volume":"12","author":"Rai BP","year":"2012","unstructured":"Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst. Rev. 12(12), CD003193 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"204209862110166","DOI":"10.1177\/20420986211016645","article-title":"Anticholinergic burden measures and older people's falls risk: a systematic prognostic review","volume":"12","author":"Stewart C","year":"2021","unstructured":"Stewart C, Taylor-Rowan M, Soiza RL, Quinn TJ, Loke YK, Myint PK. Anticholinergic burden measures and older people's falls risk: a systematic prognostic review. Ther. Adv. Drug Saf. 12, 20420986211016645 (2021).","journal-title":"Ther. Adv. Drug Saf."},{"issue":"5","key":"e_1_3_10_5_2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/ageing\/afu096","article-title":"Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review","volume":"43","author":"Fox C","year":"2014","unstructured":"Fox C, Smith T, Maidment I Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age. Ageing 43(5), 604\u2013615 (2014).","journal-title":"Age. Ageing"},{"issue":"8","key":"e_1_3_10_6_2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland CAC","year":"2019","unstructured":"Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern. Med. 179(8), 1084\u20131093 (2019).","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"e_1_3_10_7_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/nau.24536","article-title":"Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis","volume":"40","author":"Dmochowski RR","year":"2021","unstructured":"Dmochowski RR, Thai S, Iglay K Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis. Neurourol. Urodyn. 40(1), 28\u201337 (2021).","journal-title":"Neurourol. Urodyn."},{"issue":"7","key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2023","unstructured":"American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 71(7), 2052\u20132081 (2023).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"9","key":"e_1_3_10_9_2","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1111\/jgs.19500","article-title":"Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria\u00ae","volume":"73","author":"American Geriatrics Society Beers Criteria Alternatives P","year":"2025","unstructured":"American Geriatrics Society Beers Criteria Alternatives P. Steinman MA. Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria\u00ae. J. Am. Geriatr. Soc. 73(9), 2657\u20132677 (2025).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"e_1_3_10_10_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","article-title":"The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder","volume":"212","author":"Cameron AP","year":"2024","unstructured":"Cameron AP, Chung DE, Dielubanza EJ The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J. Urol. 212(1), 11\u201320 (2024).","journal-title":"J. Urol."},{"issue":"5","key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age","volume":"77","author":"Coyne KS","year":"2011","unstructured":"Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 77(5), 1081\u20131087 (2011).","journal-title":"Urology"},{"key":"e_1_3_10_12_2","volume-title":"Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA\/SUFU Guideline","author":"Gormley EA","year":"2019","unstructured":"Gormley EA, Lightner DJ, Burgio KL Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA\/SUFU Guideline. American Urological Association, MD, USA (2019)."},{"issue":"10","key":"e_1_3_10_13_2","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s00192-021-04736-8","article-title":"Anticholinergic prescribing pattern changes of urogynecology providers in response to evidence of potential dementia risk","volume":"32","author":"Menhaji K","year":"2021","unstructured":"Menhaji K, Cardenas-Trowers OO, Chang OH, Hall EF, Ringel NE, Falk KN. Anticholinergic prescribing pattern changes of urogynecology providers in response to evidence of potential dementia risk. Int. Urogynecol. J. 32(10), 2819\u20132826 (2021).","journal-title":"Int. Urogynecol. J."},{"key":"e_1_3_10_14_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.urology.2015.09.025","article-title":"Real-world patterns of care for the overactive bladder syndrome in the United States","volume":"87","author":"Goldman HB","year":"2016","unstructured":"Goldman HB, Anger JT, Esinduy CB Real-world patterns of care for the overactive bladder syndrome in the United States. Urology 87, 64\u201369 (2016).","journal-title":"Urology"},{"issue":"2","key":"e_1_3_10_15_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/MLR.0000000000000858","article-title":"Impact of new medications and $4 generic programs on overactive bladder treatment among older adults in the United States, 2000\u20132015","volume":"56","author":"Kinlaw AC","year":"2018","unstructured":"Kinlaw AC, Jonsson Funk M, Conover MM, Pate V, Markland AD, Wu JM. Impact of new medications and $4 generic programs on overactive bladder treatment among older adults in the United States, 2000\u20132015. Med. Care 56(2), 162\u2013170 (2018).","journal-title":"Med. Care"},{"issue":"2","key":"e_1_3_10_16_2","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1097\/SPV.0000000000000744","article-title":"National patterns of filled prescriptions and third-line treatment utilization for privately insured women with overactive bladder","volume":"27","author":"Linder BJ","year":"2021","unstructured":"Linder BJ, Gebhart JB, Elliott DS, Van Houten HK, Sangaralingham LR, Habermann EB. National patterns of filled prescriptions and third-line treatment utilization for privately insured women with overactive bladder. Female Pelvic Med. Reconstr. Surg. 27(2), e261\u2013e266 (2021).","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"issue":"5","key":"e_1_3_10_17_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/SPV.0000000000001301","article-title":"Despite recommendations, anticholinergics account for the majority of prescriptions to treat overactive bladder in the United States","volume":"29","author":"Carr DN","year":"2023","unstructured":"Carr DN, Macharia A, Hacker MR, Winkelman WD. Despite recommendations, anticholinergics account for the majority of prescriptions to treat overactive bladder in the United States. Urogynecology (Phila) 29(5), 497\u2013503 (2023).","journal-title":"Urogynecology (Phila)"},{"issue":"5","key":"e_1_3_10_18_2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/UPJ.0000000000000243","article-title":"Yearly trends of overactive bladder medication usage","volume":"8","author":"Chua KJ","year":"2021","unstructured":"Chua KJ, Patel HV, Tabakin A Yearly trends of overactive bladder medication usage. Urol. Pract. 8(5), 546\u2013554 (2021).","journal-title":"Urol. Pract."},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0160"},{"key":"e_1_3_10_20_2","unstructured":"Regenstrief Institute Inc. Aging Brain Program of the Indiana University Center for Aging Research. Anticholinergic Cognitive Burden Scale 2012 update (2012). Available from: (Accessed: 12 June 2024). https:\/\/corumpharmacy.com\/wp-content\/uploads\/2020\/08\/Anticholinergic-cognitive-burden-scale.pdf"},{"issue":"11","key":"e_1_3_10_21_2","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1007\/s12325-019-01098-y","article-title":"Qualitative analysis of factors influencing patient persistence and adherence to prescribed overactive bladder medication in UK primary care","volume":"36","author":"Ali M","year":"2019","unstructured":"Ali M, Grogan S, Powell S Qualitative analysis of factors influencing patient persistence and adherence to prescribed overactive bladder medication in UK primary care. Adv. Ther. 36(11), 3110\u20133122 (2019).","journal-title":"Adv. Ther."},{"issue":"9","key":"e_1_3_10_22_2","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner JS","year":"2010","unstructured":"Benner JS, Nichol MB, Rovner ES Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 105(9), 1276\u20131282 (2010).","journal-title":"BJU Int."},{"issue":"10","key":"e_1_3_10_23_2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/iju.13758","article-title":"Anticholinergic burden in the Japanese elderly population: use of antimuscarinic medications for overactive bladder patients","volume":"25","author":"Yoshida M","year":"2018","unstructured":"Yoshida M, Kato D, Nishimura T, Van Schyndle J, Uno S, Kimura T. Anticholinergic burden in the Japanese elderly population: use of antimuscarinic medications for overactive bladder patients. Int. J. Urol. 25(10), 855\u2013862 (2018).","journal-title":"Int. J. Urol."},{"key":"e_1_3_10_24_2","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2147\/CIA.S252852","article-title":"Cognitive effects of anticholinergic load in women with overactive bladder","volume":"15","author":"Araklitis G","year":"2020","unstructured":"Araklitis G, Robinson D, Cardozo L. Cognitive effects of anticholinergic load in women with overactive bladder. Clin. Interv. Aging 15, 1493\u20131503 (2020).","journal-title":"Clin. Interv. Aging"},{"issue":"4","key":"e_1_3_10_25_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s41669-021-00281-8","article-title":"The costs and healthcare resource utilization associated with anticholinergic burden in long-stay nursing home residents with overactive bladder in the US","volume":"5","author":"Chatterjee S","year":"2021","unstructured":"Chatterjee S, Walker D, Kimura T, Aparasu RR. The costs and healthcare resource utilization associated with anticholinergic burden in long-stay nursing home residents with overactive bladder in the US. Pharmacoecon. Open 5(4), 727\u2013736 (2021).","journal-title":"Pharmacoecon. Open"},{"issue":"1","key":"e_1_3_10_26_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s41669-020-00215-w","article-title":"Fall\/fracture-related healthcare costs and their association with cumulative anticholinergic burden in people with overactive bladder","volume":"5","author":"Lozano-Ortega G","year":"2021","unstructured":"Lozano-Ortega G, Schermer CR, Walker DR Fall\/fracture-related healthcare costs and their association with cumulative anticholinergic burden in people with overactive bladder. Pharmacoecon. Open 5(1), 45\u201355 (2021).","journal-title":"Pharmacoecon. Open"},{"issue":"5","key":"e_1_3_10_27_2","doi-asserted-by":"crossref","first-page":"e026391","DOI":"10.1136\/bmjopen-2018-026391","article-title":"Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study","volume":"9","author":"Szabo SM","year":"2019","unstructured":"Szabo SM, Gooch K, Schermer C Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open 9(5), e026391 (2019).","journal-title":"BMJ Open"},{"issue":"4","key":"e_1_3_10_28_2","first-page":"406","article-title":"Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics","volume":"22","author":"Yehoshua A","year":"2016","unstructured":"Yehoshua A, Chancellor M, Vasavada S Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics. J. Manag. Care Spec. Pharm. 22(4), 406\u2013413 (2016).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"4","key":"e_1_3_10_29_2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1464-410X.2011.10436.x","article-title":"Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting","volume":"109","author":"Asche CV","year":"2012","unstructured":"Asche CV, Kim J, Kulkarni AS, Chakravarti P, Andersson KE. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting. BJU Int. 109(4), 572\u2013580 (2012).","journal-title":"BJU Int."},{"key":"e_1_3_10_30_2","volume-title":"SANCTURA\u00ae (trospium chloride). Full Prescribing Information","author":"Allergan","year":"2012","unstructured":"Allergan. SANCTURA\u00ae (trospium chloride). Full Prescribing Information. Allergan, Inc, CA, USA (2012)."},{"key":"e_1_3_10_31_2","volume-title":"VESIcare\u00ae (solifenacin succinate). Full Prescribing Information","author":"Astellas Pharma US, Inc","year":"2020","unstructured":"Astellas Pharma US, Inc. VESIcare\u00ae (solifenacin succinate). Full Prescribing Information. Astellas Pharma US, Inc, IL, USA (2020)."},{"key":"e_1_3_10_32_2","volume-title":"Ditropan XL (oxybutynin chloride extended release tablets)","author":"Janssen Pharmaceuticals","year":"2016","unstructured":"Janssen Pharmaceuticals. Ditropan XL (oxybutynin chloride extended release tablets). Full Prescribing Information, NJ, USA (2016)."},{"key":"e_1_3_10_33_2","volume-title":"ENABLEX\u00ae (darifenacin). Full Prescribing Information","author":"Novartis Pharma Stein AG","year":"2008","unstructured":"Novartis Pharma Stein AG. ENABLEX\u00ae (darifenacin). Full Prescribing Information. Novartis Pharma Stein AG, Switzerland (2008)."},{"key":"e_1_3_10_34_2","volume-title":"Toviaz\u00ae (fesoterodine fumarate). Full Prescribing Information","author":"Pfizer","year":"2011","unstructured":"Pfizer. Toviaz\u00ae (fesoterodine fumarate). Full Prescribing Information. Pfizer Inc, NY, USA (2011)."},{"key":"e_1_3_10_35_2","volume-title":"Detrol (tolterodine tartrate). Full Prescribing Information","author":"Pfizer","year":"2012","unstructured":"Pfizer. Detrol (tolterodine tartrate). Full Prescribing Information. Pfizer, NY, USA (2012)."},{"issue":"3","key":"e_1_3_10_36_2","first-page":"337","article-title":"Pharmacologic management of overactive bladder","volume":"2","author":"Lam S","year":"2007","unstructured":"Lam S, Hilas O. Pharmacologic management of overactive bladder. Clin. Interv. Aging 2(3), 337\u2013345 (2007).","journal-title":"Clin. Interv. Aging"},{"key":"e_1_3_10_37_2","unstructured":"National Institute for Diabetes and Digestive and Kidney Diseases. Definition & facts of urinary retention (2019). Available from: (Accessed: 15 August 2025). https:\/\/www.niddk.nih.gov\/health-information\/urologic-diseases\/urinary-retention\/definition-facts"},{"key":"e_1_3_10_38_2","doi-asserted-by":"crossref","first-page":"772387","DOI":"10.3389\/fpsyt.2021.772387","article-title":"Risk factors for delirium in the palliative care population: a systematic review and meta-analysis","volume":"12","author":"Guo D","year":"2021","unstructured":"Guo D, Lin T, Deng C, Zheng Y, Gao L, Yue J. Risk factors for delirium in the palliative care population: a systematic review and meta-analysis. Front. Psych. 12, 772387 (2021).","journal-title":"Front. Psych."},{"key":"e_1_3_10_39_2","volume-title":"Effexor XR (venlafaxine). Full Prescribing Information","author":"Pfizer","year":"2017","unstructured":"Pfizer. Effexor XR (venlafaxine). Full Prescribing Information. Pfizer (2017)."},{"issue":"9","key":"e_1_3_10_40_2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1532-5415.2010.03011.x","article-title":"The blood-brain barrier: geriatric relevance of a critical brain-body interface","volume":"58","author":"Zeevi N","year":"2010","unstructured":"Zeevi N, Pachter J, McCullough LD, Wolfson L, Kuchel GA. The blood-brain barrier: geriatric relevance of a critical brain-body interface. J. Am. Geriatr. Soc. 58(9), 1749\u20131757 (2010).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"2","key":"e_1_3_10_41_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1755-5949.2011.00248.x","article-title":"Anticholinergics for overactive bladder therapy: central nervous system effects","volume":"18","author":"Chancellor M","year":"2012","unstructured":"Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci. Ther. 18(2), 167\u2013174 (2012).","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"e_1_3_10_42_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1186\/s12877-024-05197-6","article-title":"Differences of anticholinergic drug burden between older hospitalized patients with and without delirium: a systematic review and meta-analysis based on prospective cohort studies","volume":"24","author":"Ieong C","year":"2024","unstructured":"Ieong C, Chen T, Chen S Differences of anticholinergic drug burden between older hospitalized patients with and without delirium: a systematic review and meta-analysis based on prospective cohort studies. BMC Geriatr. 24(1), 599 (2024).","journal-title":"BMC Geriatr."},{"issue":"8","key":"e_1_3_10_43_2","first-page":"CD015196","article-title":"Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia","volume":"8","author":"Taylor-Rowan M","year":"2022","unstructured":"Taylor-Rowan M, Kraia O, Kolliopoulou C Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia. Cochrane Database Syst. Rev. 8(8), CD015196 (2022).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_10_44_2","first-page":"S139","article-title":"A retrospective study of the prevalence of anticholinergic poly-pharmacy use and its associated outcomes among Medicare patients with overactive bladder","volume":"69","author":"Campbell N","year":"2021","unstructured":"Campbell N, Shiozawa A, Epstein A, Walker D, Lockefeer A, Hines L. A retrospective study of the prevalence of anticholinergic poly-pharmacy use and its associated outcomes among Medicare patients with overactive bladder. J. Am. Geriatr. Soc. 69, S139 (2021).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"e_1_3_10_45_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12877-022-03279-x","article-title":"Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis","volume":"22","author":"Delara M","year":"2022","unstructured":"Delara M, Murray L, Jafari B Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis. BMC Geriatr. 22(1), 601 (2022).","journal-title":"BMC Geriatr."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:31:07Z","timestamp":1765884667000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.57264\/cer-2025-0054"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0054","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"e250054"}}